Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 14;97(11):545-547.
doi: 10.1212/WNL.0000000000012452. Epub 2021 Jul 7.

Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks

David S Knopman  1 , Joel S Perlmutter  2
Affiliations
Comment

Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks

David S Knopman et al. Neurology. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. US Food and Drug Administration. FDA grants accelerated approval for Alzheimer’s drug. 2021. Accessed. June 7, 2021. fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-...
    1. Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17(4):696–701. - PubMed
    1. Kuller LH, Lopez OL. ENGAGE and EMERGE: truth and consequences? Alzheimers Dement. 2021;17(4):692–695. - PMC - PubMed
    1. Cummings J, Aisen P, Lemere C, et al. . Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther. 2021;13(1):98. - PMC - PubMed
    1. EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients with Early Alzheimer's Disease. 2019. Accessed December 8, 2019. investors.biogen.com/static-files/ddd45672-9c7e-4c99-8a06-3b557697c06f

MeSH terms

Substances